ACT UP, 268-271, 298 adenylate cyclase, see adenylyl cyclase adenylyl cyclase ibogaine potentiation of morphine effect on,7 ibogaine potentiation of serotonin effect on,12, 146 mu-opioid inhibition of, 98-99 Adriaans, Nico Dutch Junkiebond and, 253, 283-284 Dutch Addict Self-Help (DASH) and, 283-4, 298, 302, 311 Erasmus University and, 258-259, 271, 298 view on importance of peer counseling in ibogaine treatment, 290 acetylcholine, EEG and, 9, 28-29 muscarinic acetylcholine receptors, iboga alkaloids and, 9, 41, 50 nicotinic acetylcholine receptors, iboga alkaloids and, 6, 9-10, 41, 50-51 REM sleep and, 29 affinity of iboga alkaloids at various receptor sites, tables, 41, 81, 167 anomie, 238 anxiety cocaine withdrawal and, 146-148 ibogaine and, 227-234 kappa-opioid receptors and, 231-232 Bastiaans, Jan, Dr. ibogaine treatments in the Netherlands, and, 260, 285, 298 LSD and, 260 Beal, Dana (see also Cures-not-Wars), 271-272 benzodiazepine receptor, 179 binding, space and time, iboga and, 239, 244 Bin-Wahad, Dhoruba, 272 Bwiti estimated dosages of iboga alkaloids used, table, 242 sacramental use of iboga, 30, 235-247, 294 work of the ancestors, iboga and, 239, 245 cannabis, market separation from hard drugs, 270 cardiovascular effects, iboga alkaloids, 25, 49, 166-167 cerebellar Purkinje cells, climbing fiber synapses originating from the inferior olive, excitoxicity and, 12, 184-185 charismatic group, 30 Chemical Abstracts ibogamine skeleton numbering, 3, (see A Note Concerning the Numbering of Iboga Alkaloids) Christiana, Copenhagen, 261-263 civil disobedience, 267 Clouet, Doris, Dr., 252-253 Cocaine cardiovascular effects of ibogaine and 166 dopamine efflux in the rat NAc, iboga alkaloids and, 15-16 dopamine efflux in mouse brain slice, ibogaine and effect of kappa-opioid antagonist, 8 EEG effects of ibogaine and, 196-200 locomotor response to, iboga alkaloids and, 46-47, 51 self- administration, iboga alkaloids and 5, 12-13, 16, 22, 42,45-46, 48, 119, 127- 129 sensitization, 15-16, 47-48 stereotypy and, 46-47 withdrawal anxiety, ibogaine and, 146-148 colonialism 30, 237-40 corticosterone secretion rat, ibogaine and, 200-201 rat, ibogaine and noribogaine and, 100-103 craving, drug animal model, 220-221 measurement in humans utilizing the Heroin Craving Questionnaire (HCQ-29), 163, 165 effects on with ibogaine in humans, 16-17, 165-169, 284, 287 Cures-not-Wars, 264, 272, 275 cytochrome P450 2D6 (CYPD2D6), 82-83, 158-161 Czech Republic, ibogaine scene in, 264-265 DASH (Dutch Addict Self-Help), 253, 257-58 Doors of Perception, The, 251 dopamine brain tissue levels, effect of ibogaine on, 9, 87-91, 108, 199-202 efflux, NAc, cocaine, iboga alkaloids and, 15-16, 47-48 efflux, NAc, morphine, iboga alkaloids and 15, 45 efflux, NAc, nicotine, iboga alkaloids and 15-16, 47-48 receptor affinity, iboga alkaloids, 9, 41, transporter, iboga alkaloids and, 9, 86-87, 117 Dole, Vincent P. Dr., 290, 312 DOM (2,5-dimethoxy-4-methylamphetamine), 10, 63, 66-69, 71 Drug discrimination beta-carbolines in ibogaine-trained animals, 11, 69-71 fixed ratio schedule, 64 NMDA antagonists in ibogaine-trained animals, 11, 72 nonessential stimulus components, ibogaine, 10-11, 66-69 noribogaine in ibogaine-trained animals, 11, 74-75 opioids in ibogaine-trained animals, 73-74 serotonergic agents in ibogaine-trained animals, 8, 10-11, 66-69, 75 sigma ligands in ibogaine-trained animals, 74-75 dynorphin, ibogaine and, 11 ECoG (electrocortigogram) 194-200 EEG (electroencephalogram) ibogaine and, 9, 24, 28-29 effect of cocaine in rats pretreated with ibogaine 194-200 learning and, 29-30 ethanol self-administration, iboga alkaloids and, 12, 51, 127 Erasmus University, Rotterdam, 253-254, 257-259, 271, 298 eye movements, observations reported by treatment guides, 30 fatalities, 25-27 FDA (US Food and Drug Administration) approval of IND submitted by D. Mash, 5, 255, 303 scheduling of ibogaine, 4 fenfluramine, 8, 66, 92, 102, 201 fluoxetine, 11, 69 fluvoxamine, 69 focus group for participants in DASH treatments, 258, 284 Fluoro-Jade, cerebellar degeneration and, 23, 208 Frenken, Geerte, 257 Gabon 4, 253, 265, 294 GFAP (glial fibrillary acid protein), 22-23, 106, 203-204 gender differences bioavailability, 19-20, 84 kinetics and metabolism of ibogaine and noribogaine in rats, 84-85, 107-108 neuropathology, 22 visual phenomena related to ibogaine in humans, 256 Glick, Stanley, Dr., 253 glycine, 7, 58-59, 61 Goutarel, Robert, 29-30, 256, 275 guide, treatment, 17, 285-288, 300 hallucinations, 18-19, 286 haloperidol, sigma receptor and, 174, 176 harm reduction, 267-268, 270-272, 278, 290 harmaline 107, 174, 184-185, 188 Harms, Josien 257, 283 heroin self-administration, ibogaine and, 12-13 smoking, 26 withdrawal, human, ibogaine and 17, 155-172, 284-298, ibogaine chemical properties, 2-3 mechanisms of action, 6-10, 40-41, 49-51, 55-62, 115-133, 140-142, 167-169 opioid receptors and, 7-8, 41, 167-169 pharmacokinetics, see pharmacokinetics, ibogaine possible differences related to manufacturing source, 119 price, Slovenia, 261 scheduling, 4, 250-251, 268, 272 Ibogaine Mailing List 6, 262, 276 Ibogaine Story, The 264, 275 ICASH (International Coalition of Addict Self-Help) 5, 283, 298-299 INTASH (International Addict Self-Help) 235, 239-243, 254, 257, 283, 285-286, 290, 302 Internet, 6, 262, 264, 276-277 Isbell, Harris, Dr., 4 Junkiebond, Dutch, 253, 268, 270-271, 283 Kabouters, 269 Kaplan, Charles, Dr., 258-259, 284 Ka-Tzetnik 135633 (Yehiel De-Nur), 260 Kleber, Herbert, Dr. 284 Lambarène, 4, 115 LeMen and Taylor ibogamine skeleton numbering, 3, ( see A Note Concerning the Numbering of Iboga Alkaloids) Lieberman, Dan, 263, 265-266 locomotor activity cocaine, iboga alkaloids, and 14-15, 46-48, 91 morphine, iboga alkaloids and, 14-15, 44-45 stereotypy and, 15, 47 long-term outcomes, ibogaine treatments, 17-18, 156 Lotsof, Howard initial observations of ibogaine effect in humans, 4, 251-252, 294-295 patents for use of ibogaine in drug dependence and, 4-5, 253 NDA International and, 253-254 LSD (lysergic acid diethylamide) Jan Bastiaans and, 260 5HT2A receptor and, 66-69 Mash, Deborah, Dr., FDA and, 5, 166, 254-55 St. Kitts and, 17, 25, 155-171, 255 Memantine, 57, 59, 61 18-Methoxycoronaridine (18-MC) drug self-administration and, 13, 40-46, 48, 51 locomotor behavior and, 44-48 morphine withdrawal and, 40, 43-44, 47, 51 NMDA receptors and, 41,44-45, 49, 60-61 opioid receptors and, 41, 44-45, 49, 51 serotonin and, 41, 49, 51 sigma receptors and 41, 49, 79-83 morphine dopamine efflux in NAc, iboga alkaloids and 15, 45 locomotor response to, iboga alkaloids and, 14, 44 modulation of effects by ibogaine, 212 self-administration, iboga alkaloids and, 42-43, 213-214 withdrawal, animal, effect of iboga alkaloids, 13-14, 40, 43-44, 51, 98-99, 215- 219 mouse differences from the rat regarding ibogaine with regard to ibogaine effect on locomotor response to cocaine, 15 differences from the rat regarding ibogaine neurotoxic effects, 207-208 knockout, 117, 125, 128 morphine withdrawal and, 14 Naranjo, Claudio, Dr., 4, NDA International, 15, 251, 253-255, 259-260, 268, 298, 303 NDE (near death experience), 30-31 neurotensin-like immunoreactivity (NTLI), ibogaine and, 11 neurotoxicity human evidence 24-25 neuropathological studies in animals 22-24, 105-107, 202-209 sigma receptors and, 173-174, 176, 184-186, 188 NIAD (Netherlands Institute for Alcohol and Drugs) 259, 285 nicotine dopamine efflux, iboga alkaloids and, 10, 15-16, 45, 47 self-administration/ preference, iboga alkaloids and, 5, 12-13, 33, 42, 46 nicotinic acetylcholine receptor, see acetylcholine NIDA (National Institute on Drug Abuse), 2, 5 252-254, 259, 267, 269, 271-275, 278 NIDA Ibogaine Review Meeting, March 1995, 5, 17 NIH (National Institutes of Health), 273 NMDA (N-methyl-D-aspartate) affinity of ibogaine for the NMDA receptor 6-7, 41, 56-60, 81, 167 discriminative stimulus of ibogaine, and, 11, 72-73, effects of NMDA antagonists in opioid withdrawal 59 functional evidence for ibogaine as NMDA antagonist 7, 56-60, 184 18-MC and, 41,44-45, 49, 60-61 noribogaine and 41, 60, 81, 105, 167 sigma receptors and, 174-175, 184-185 norharman, effect on morphine withdrawal, 14 noribogaine (10-hydroxyibogamine) identification as a primary metabolite of ibogaine, 81-82, 157-158 NMDA receptors and 41, 60, 81, 105, 167 opioid receptors and, 7-8, 41, 81, 108, 167-169 serotonin receptor interactions, 41, 81, 167 serotonin release in NAc and, 47 sigma receptors and, 179-187 tissue dopamine levels and, 108 normalization, 252, 271 nucleus accumbens (NAc) core vs. shell regions, 12, 15-16 dopamine efflux in response to drugs, effects of iboga alkaloids, 15-16, 45, 47-48 olivocerebellar projection, 23, 184-185 oneiric/ oneirophrenic effects, 18, 275, 309 opioid receptors, interactions with iboga alkaloids, ibogaine 8, 41, 167-169 18-MC 41, 44-45, 49, 51 noribogaine 7-8, 41, 81, 108, 167-169 Parker, Jon, 24 panoramic memory, 18, 28, 30, 287-288, 299-301 pharmacokinetics, ibogaine animal pharmacokinetic studies 19-20, 81-85, 95, 161 gender and gonadectomy and, 84-85 heterogeneity among CYP isoforms, 20, 158-160, 162 humans, 19-20, 159-160 place preference amphetamine, ibogaine and, 220 morphine, ibogaine and, 220 plus maze, 146-148, 151, 229-232 political theater, tactics of, 269-271 prolactin secretion rat, effect of ibogaine 200-201 rat, effect of ibogaine and noribogaine 100-103 Provos, 269 reinstatement paradigm, 220 REM sleep 29-30 Resinovic, Marko, 260-261 Rock Against Racism, 272 runway paradigm, rewarding and aversive effects of